intranasal

[키워드] administration alveolar macrophage animal model binding blockade blunting cells circulating Clinical improvement clinical trial compassionate use COVID-19 Cytokine release syndrome death described driven by FDA approval GM-CSF healthy controls help Hospitalization hyperinflammation IL-6 Increased Inflammatory cytokine Inflammatory response inflammatory signaling interferon-γ intranasal intravenous dose involved lung damage Macrophage macrophages mavrilimumab mechanical ventilation Mild symptom monoclonal antibodies monoclonal antibody MOST outcomes Oxygenation patients with COVID-19 placebo-controlled trial produced proliferation Prospective provided Randomized rationale receptor Respiratory failure respiratory infections SARS-CoV-2 Severe case severe pneumonia Signaling Strategy syndrome T-cells targeting tested treated Trial while
[DOI] 10.3389/fimmu.2020.01625 PMC 바로가기 [Article Type] Immunology